Joanne Rogin, MD
Neurology · Golden Valley, MNNPI 1528006418
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $45,145 of the $60,746 with a category attached, or 74.3%. 11 manufacturers reported payments, led by SK Life Science, Inc. at 39.0% of the total. Reporting peaked in 2019 at $21,258 and has fallen 98.8% since, to $265 in 2025. Among neurology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $682.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$24K
- Eisai Inc.$16K
- Sunovion Pharmaceuticals Inc.$7K
- Catalyst Pharmaceuticals, Inc.$6K
- UCB, Inc.$5K
- UCB SA$2K
- plus $1K from 5 others
Across 76 payments — averaging $4896.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$120K
- SK Life Science, Inc.$106K
- UCB SA$65K
- Sunovion Pharmaceuticals Inc.$39K
- UCB Biosciences Inc.$21K
- Pfizer$21K
What the payments were for
- Consulting fees$7,11012%
- Speaking & faculty fees$45,14574%
- Travel & lodging$6,03210%
- Food & beverage$2,4384%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 25 | $23,680 |
| Eisai Inc. | 15 | $16,233 |
| Sunovion Pharmaceuticals Inc. | 7 | $6,752 |
| Catalyst Pharmaceuticals, Inc. | 6 | $5,653 |
| UCB, Inc. | 16 | $5,485 |
| UCB SA | 11 | $1,550 |
| Aquestive Therapeutics, Inc. | 1 | $1,020 |
| Jazz Pharmaceuticals Inc. | 5 | $282 |
| Greenwich Biosciences, Inc. | 1 | $50 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| GE HealthCare | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fycompa$21,722
- XCOPRI$17,163
- APTIOM$6,747
- Cenobamate$5,925
- Briviact$3,250
How this compares
$60,746 in reported general payments places this provider in the 95th percentile of 434 neurology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 48 | $2,461 |
| Levetiracetam ErLevetiracetam | 11 | $1,427 |
| Lamotrigine | 35 | $1,404 |
| Lacosamide | 22 | $1,172 |
| Oxcarbazepine | 15 | $608 |
| Primidone | 12 | $490 |
| Pregabalin | 12 | $267 |
| Gabapentin | 13 | $262 |
| Trazodone Hcl | 14 | $232 |
| Topiramate | 12 | $115 |
Paid to pharmacies, not to this prescriber.
Other neurology in Golden Valley
- Jonathan CalkwoodGolden Valley$493K
- Irfan AltafullahGolden Valley$203K
- Jessica StulcGolden Valley$199K
- Akram DastagirGolden Valley$174K
- Jessica HeiringGolden Valley$149K
- Brent BerryGolden Valley$141K
- Xiaoming DongGolden Valley$47K
- Randall SchapiroGolden Valley$19K
- Jeffery AllenMinneapolis$1.1M
- Alejandro RabinsteinRochester$305K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.